Abstract: Disclosed is the genomic sequence for E. coli O55:H7 as well as compositions, methods, and kits for detecting, identifying and distinguishing E. coli O55:H7 from non-O55:H7 strains. In some embodiments, isolated nucleic acid compositions unique and/or specific to E. coli O55:H7 are described. Methods of detection and/or indentifying E. coli O55:H7 comprising detecting at least one nucleic acid sequences comprising or derived from SEQ ID NO:1-5, SEQ ID NO: 66, SEQ ID NO: 252, SEQ ID NO: 1113, and SEQ ID NO: 1461, are described. Primer and probe compositions and methods of use of primers and probes are also provided. Kits for identification of E. coli O55:H7 are also described.

Abstract: The present invention provides nucleic acid molecules containing nucleotide sequences encoding helminth aminopeptidase enzymes, and antigenic fragments and functionally-equivalent variants thereof, their use in the preparation of vaccines, for use against helminth parasites, and synthetic polypeptides encoded by them.

Abstract: The present invention provides nucleic acid molecules containing nucleotide sequences encoding helminth aminopeptidase enzymes, and antigenic fragments and functionally-equivalent variants thereof, their use in the preparation of vaccines, for use against helminth parasites, and synthetic polypetides encoded by them.

Abstract: The present invention provides nucleic acid molecules containing nucleotide sequences encoding helminth aminopeptidase enzymes, and antigenic fragments and functionally-equivalent variants thereof, their use in the preparation of vaccines for use against helminth parasites, and synthetic polypeptides encoded by them.

Abstract: A suspension comprising an aqueous structured surfactant having suspended therein particles or droplets of a substantially water insoluble or sparingly soluble biocidal or agrochemical active substance in a weight ratio of total surfactant to said active substance of less than 20:1.

Abstract: A DNA sequence encoding a fusion protein comprising influenza virus HA, at a site of which normally occupied by a natural antigenic epitope thereof a different antigenic epitope is provided, is incorporated in a vector which is capable of expressing the fusion protein when provided in a eucaryotic host. When in the form of a viral vector such as a recombinant vaccinia virus, the vector can be used as a vaccine. Alternatively, the fusion protein expressed by the host can be recovered and provided as a vaccine.

Abstract: The use of a stabiliser comprising a hydrophilic polymeric chain of more than four hydrophilic monomer groups and/or having a mass greater than 300 amu, linked at one end to a hydrocarbon-soluble hydrophobic group to reduce or prevent the flocculation of systems comprising a flocculable surfactant and a liquid medium which is capable of flocculating the surfactant and in which the stabiliser is capable of existing as a micellar solution at a concentration of at least 1% by weight.

Abstract: The use of a stabiliser comprising a hydrophilic polymeric chain of more than four hydrophilic monomer groups and/or having a mass greater than 300 amu, linked at one end to a hydrocarbon-soluble hydrophobic group to reduce or prevent the flocculation of systems comprising a flocculable surfactant and a liquid medium which is capable of flocculating the surfactant and in which the stabiliser is capable of existing as a micellar solution at a concentration of at least 1% by weight.

Abstract: The present invention provides nucleic acid molecules containing nucleotide sequences encoding helminth aminopeptidase enzymes, and antigenic fragments and functionally-equivalent variants thereof, their use in the preparation of vaccines for use against helminth parasites, and synthetic polypeptides encoded by them.

Abstract: A DNA sequence encoding a fusion protein comprising influenza virus HA, at a site of which normally occupied by a natural antigenic epitope thereof a different antigenic epitope is provided, is incorporated in a vector which is capable of expressing the fusion protein when provided in a eucaryotic host. When in the form of a viral vector such as a recombinant vaccinia virus, the vector can be used as a vaccine. Alternatively, the fusion protein expressed by the host can be recovered and provided as a vaccine.